Tetrahydrocannabinol (Delta 9-THC) Treatment in Chronic Central Neuropathic Pain and Fibromyalgia Patients: Results of a Multicenter Survey

Table 3

Estimated pain intensity (VRS) and maximum/minimum pain (NRS) recorded in the subgroups of “inflammatory central neuropathy”—“central neuropathic pain due to trauma”—“fibromyalgia” prior to and during/after delta 9-THC therapy. No significant differences between the groups could be analysed. In each group, delta 9-THC medication caused a noticeable amelioration of pain.

	Inflammatory central neuropathy		Central neuropathy due to trauma		Fibromyalgia
	Prior to	After	Prior to	After	Prior to	After
	Delta 9-THC medication		Delta 9-THC medication		Delta 9-THC medication
Pain intensity	7.6±1.7	4.2±1.9	7.6±1.4	3.8±1.5	7.9±1.5	4.4±1.5
(VRS, 0–10)
Max. pain	7.6±1.7	4.9±2.4	9.3±1	5.3±1.7	9.3±1.1	6.1±2.1
(NRS, 0–10)
Min. pain	5.4±1.8	2.1±1.5	6.0±1	2.9±1.9	6.6±2	3.0±1.8
(NRS, 0–10)